San Diego, CA – July 22, 2025 –Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive ...
SAN DIEGO & BRISTOL, Pa. & CAMBRIDGE, England--(BUSINESS WIRE)--Dr. Jonathan Goldman, CEO, announced that Abzena has augmented existing 500 L scale biologics equipment with 20m$ of investment into two ...
Roughly one year after dropping designs on a $200 million biologics plant in North Carolina, antibody-drug conjugate specialist Abzena has snared a fresh round of funding to overhaul manufacturing on ...
Beringea, the growth capital investor that manages the ProVen Venture Capital Trusts, has announced that Abzena Plc, previously known as Polytherics, has raised £20 million, by way of a placing of 25 ...
EXTON, Pa. & SAN DIEGO--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody ...
SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- Abzena, the leading end-to-end CDMO for complex biologics and bioconjugates, has co-authored a publication with the US Food and Drug Administration (FDA) ...
Abzena, a leading CDMO providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced a significant upgrade to its research and ...
Abzena has acquired contract development and manufacturing organization (CDMO) PacificGMP for $8.4 million, the companies said today, in a deal that gives the buyer a U.S. base of operations while ...
SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board ...
Abzena and France-based Mabqia greed to collaborate on the integration of Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, a project designed to offer ...
LabZient™ combines predictive in-silico evaluation with well-established and vetted laboratory methods that de-risk the application of platform analytical procedures. In doing so, LabZient™ removes ...
Immunome is a biopharmaceutical company utilizing our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results